SAM
BTAI icon

Sectoral Asset Management’s BioXcel Therapeutics BTAI Stock Holding History

Sectoral Asset Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,822
Closed -$1.31M – 120
2022
Q4 		$1.31M Buy
+3,822
New +$924K 0.25% 91

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Sectoral Asset Management's BTAI Position: Q1 2023 in Review

Sectoral Asset Management sold out of BioXcel Therapeutics (BTAI) in Q1 2023, closing a stake of 3,822 shares — an estimated $1.31M sold.

Sectoral Asset Management first reported a position in BTAI in Q4 2022 and held it in 1 quarter. The position peaked at $1.31M in Q4 2022. 96 funds tracked by Wall St. Rank hold BTAI as of Q1 2023.

  • Sectoral Asset Management reported no remaining BioXcel Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Sectoral Asset Management sold 3,822 BioXcel Therapeutics shares in Q1 2023, an estimated $1.31M.
  • Sectoral Asset Management first reported a position in BioXcel Therapeutics in Q4 2022 and held it in 1 quarter.
  • Sectoral Asset Management's BioXcel Therapeutics position peaked at $1.31M in Q4 2022.
  • 96 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2023.

Based on Sectoral Asset Management's 13F filing for Q1 2023, filed 12 May 2023.